The usefulness of salicylates in T2D was assessed in a meta-analysis involving 13,464 patients, that revealed that while any dose of salicylates could significantly reduce HbA1c level, only high doses (≥3000 mg/day) could effectively reduce fasting plasma glucose and triglycerides with a simultaneous increase in plasma fasting insulin level with a relatively low risk of adverse effects [157]. The gene discussed is INS; the disease is type 2 diabetes mellitus.